Skip to main content

Table 1 Baseline characteristics

From: Lymphadenectomy in ovarian cancers: a meta-analysis of hazard ratios from randomized clinical trials

Parameters

Harter (2019)

Panici 2005

Maggioni 2006

Case

N=323

n (%)

Control

N=324

n (%)

Case

N=216

n (%)

Control

N=211

n (%)

Case

N=138

n (%)

Control

N=130

n (%)

Age (years)

SD

60

21–83

60

23–78

53

45–61

56

47–62

51

43–60

52

44–59

Median CA 125

416

347

-

-

-

-

FIGO stage

 1–2A

15

17

-

-

135

129

 2B–3A

41

52

-

-

-

-

 3B–4

261

244

216

211

-

-

 Missing data

6

11

-

-

3

1

Residual tumor

 None

321 (99.4)

322 (99.4)

80 (37)

79 (37.40)

133 ( 96.4)

126 (96.9)

 <1cm

N M

NM

130 (60.2)

118 (55.9)

5 (3.6)

4 (3.1)

 >1 cm

NM

NM

4 (1.9)

12 (5.7)

-

-

 Missing data

NM

NM

2 (0.9)

2 (0.9)

-

-

Median number of resected nodes (number)

 Pelvic

22

-

28.5

1

24

3.5

 Paraaortic

35

-

23

1

21

1

 Both

57

-

51.5

4

47

5.5

Tumor grade

 1

-

-

19 (8.8)

11 (5.2)

30 (21.7)

20 (15.4)

 2

-

-

50 ( 23.1)

37 (17.5)

29 (21)

41 (31.5)

 3

-

-

142 (65.7)

160 (75.8)

72 (52.2)

65 (50)

 Missing data

-

-

5 (2.3)

3 (1.4)

7 (5.1)

4 (3.1)

Cell type

 Serous

246 (73.1)

248 (76.6)

132 (62.6)

155 (71.8)

61 (44.2)

43 (33.1)

 Endometriod

16 (4.9)

18 (4.5)

28 (13.3)

21 (9.6)

24 (17.4)

34 (26.2)

 Mucinous

3 (0.9)

6 (1.9)

6 (2.8)

4 (1.9)

14 (10.1)

22 (16.9)

 Clear cell

7 (2.2)

7 (2.2)

12 (5.7)

4 (1.9)

16 (11.6)

19 (14.6)

 Undifferentiated

34 (10.5)

28 (8.6)

23 (10.9)

18 (8.3)

7 (5.1)

8 (6.1)

 Other

15 (4.6)

14 (4.3)

8 (3.8)

12 (5.6)

8 (5.8)

2 (1.5)

 Borderline tumor

2 (0.6)

3 (0.9)

-

-

-

-

 Missing data

-

-

2 (0.9)

2 (0.9)

8 (5.8)

2 (1.5)

Jadad score (R+B+W)

(1+1) + (0) + (1)

(1+1) + (0) + (1)

(1+1) + (0) + (1)

  1. NM not mentioned, R randomisation, B blinding, W withdrawals